Detalhe da pesquisa
1.
Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control.
J Allergy Clin Immunol
; 152(4): 876-886, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37315813
2.
Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes.
Am J Respir Crit Care Med
; 206(5): 545-553, 2022 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35549845
3.
Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma.
Eur Respir J
; 59(4)2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34561291
4.
A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
Clin Exp Allergy
; 50(12): 1342-1351, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32909660
5.
Using prednisolone and cortisol assays to assess adherence in oral corticosteroid dependant asthma: An analysis of test-retest repeatability.
Pulm Pharmacol Ther
; 64: 101951, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33045343
6.
Change in biomarkers of type-2 inflammation following severe exacerbations of asthma.
Thorax
; 74(1): 95-98, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30021810
7.
Change in type-2 biomarkers and related cytokines with prednisolone in uncontrolled severe oral corticosteroid dependent asthmatics: an interventional open-label study.
Thorax
; 74(8): 806-809, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-30940770
8.
Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.
Pulm Pharmacol Ther
; 46: 88-98, 2017 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-28843617
9.
Roles of Periostin in Respiratory Disorders.
Am J Respir Crit Care Med
; 193(9): 949-56, 2016 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26756066
10.
Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK).
Thorax
; 71(2): 187-9, 2016 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-26205878
11.
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.
Thorax
; 70(8): 748-56, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-26001563
12.
Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort.
Eur Respir J
; 46(5): 1308-21, 2015 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-26357963
13.
Lebrikizumab treatment in adults with asthma.
N Engl J Med
; 365(12): 1088-98, 2011 Sep 22.
Artigo
Inglês
| MEDLINE | ID: mdl-21812663
14.
Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.
J Allergy Clin Immunol
; 132(3): 567-574.e12, 2013 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-23726041
15.
Clarification of epicutaneous immunotherapy trial phase 3 results and methods for qualitative survey design.
Ann Allergy Asthma Immunol
; 121(5): 641-642, 2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30389085
16.
Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab.
J Allergy Clin Immunol
; 139(5): 1682-1684.e3, 2017 05.
Artigo
Inglês
| MEDLINE | ID: mdl-28238745
17.
A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex.
J Allergy Clin Immunol Pract
; 11(4): 1233-1242.e5, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36621603
18.
Serum periostin is associated with type 2 immunity in severe asthma.
J Allergy Clin Immunol
; 137(6): 1904-1907.e2, 2016 06.
Artigo
Inglês
| MEDLINE | ID: mdl-27061252
19.
Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS).
Clin Transl Allergy
; 12(7): e12176, 2022 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-35846226
20.
Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.
Lancet Respir Med
; 9(1): 57-68, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32916135